These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20159523)

  • 21. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
    Mosquera C; Maglic D; Zervos EE
    Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular therapy in pancreatic adenocarcinoma.
    MacKenzie MJ
    Lancet Oncol; 2004 Sep; 5(9):541-9. PubMed ID: 15337483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances and future trends in the targeted therapy of metastatic gastric cancer.
    Al-Batran SE; Werner D
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):555-69. PubMed ID: 24665840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma.
    Engelhardt K; Riley C; Cooke L; Mahadevan D
    Curr Drug Discov Technol; 2006 Dec; 3(4):231-43. PubMed ID: 17430101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-gene signaling pathways in pancreatic cancer.
    Drakaki A; Iliopoulos D
    Biomed J; 2013; 36(5):200-8. PubMed ID: 24225187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer.
    Tempero MA; Klimstra D; Berlin J; Hollingsworth T; Kim P; Merchant N; Moore M; Pleskow D; Wang-Gillam A; Lowy AM
    Clin Cancer Res; 2013 Feb; 19(3):538-40. PubMed ID: 23344262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarkers in pancreatic adenocarcinoma.
    Joza N; Saif MW
    JOP; 2014 Jul; 15(4):308-9. PubMed ID: 25076328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting heat shock response pathways to treat pancreatic cancer.
    Xia Y; Rocchi P; Iovanna JL; Peng L
    Drug Discov Today; 2012 Jan; 17(1-2):35-43. PubMed ID: 21986108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Refocusing the war on cancer: the critical role of personalized treatment.
    Potti A; Schilsky RL; Nevins JR
    Sci Transl Med; 2010 Apr; 2(28):28cm13. PubMed ID: 20410527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges in developing targeted therapy for pancreatic adenocarcinoma.
    Mahalingam D; Giles F
    Expert Opin Ther Targets; 2008 Nov; 12(11):1389-401. PubMed ID: 18851695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pancreatic cancer: molecular pathogenesis and new therapeutic targets.
    Wong HH; Lemoine NR
    Nat Rev Gastroenterol Hepatol; 2009 Jul; 6(7):412-22. PubMed ID: 19506583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms and Drug Targets for Pancreatic Cancer Chemoprevention.
    Dhar D; Raina K; Agarwal R
    Curr Med Chem; 2018; 25(22):2545-2565. PubMed ID: 28322154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic antibodies for the treatment of pancreatic cancer.
    Chames P; Kerfelec B; Baty D
    ScientificWorldJournal; 2010 Jun; 10():1107-20. PubMed ID: 20563534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biotherapeutic approaches to pancreatic cancer.
    Rosenberg L; Lipsett M
    Expert Opin Biol Ther; 2003 Apr; 3(2):319-37. PubMed ID: 12662145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current approaches and future strategies for pancreatic carcinoma.
    Wolff RA; Chiao P; Lenzi R; Pisters PW; Lee JE; Janjan NA; Crane CH; Evans DB; Abbruzzese JL
    Invest New Drugs; 2000 Feb; 18(1):43-56. PubMed ID: 10830140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted therapies for pancreatic cancer.
    Danovi SA; Wong HH; Lemoine NR
    Br Med Bull; 2008; 87():97-130. PubMed ID: 18753179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel targets in pancreatic cancer: focus on future paths to therapy.
    Cohen SJ; Burtness BA
    Expert Opin Ther Targets; 2006 Oct; 10(5):771-5. PubMed ID: 16981833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The medical management of pancreatic cancer: a review.
    McKenna S; Eatock M
    Oncologist; 2003; 8(2):149-60. PubMed ID: 12697940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. D-dimers revisited: a new marker of pancreatic cancer.
    Durczynski A; Kumor A; Hogendorf P; Szymanski D; Poznanska G; Grzelak P; Strzelczyk J
    Am J Clin Oncol; 2014 Dec; 37(6):642. PubMed ID: 24662268
    [No Abstract]   [Full Text] [Related]  

  • 40. Emerging drugs for the treatment of pancreatic cancer.
    Van Laethem JL; Marechal R
    Expert Opin Emerg Drugs; 2007 May; 12(2):301-11. PubMed ID: 17604503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.